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a  b  s  t  r  a  c  t
The objective of this study was to evaluate the consensus of expert societies and published
guidelines on the management of ulcerative colitis, and to compare with the experience of
the  authors, in order to standardize procedures that would help the reasoning and decision-
making process of the physician. A search was performed in scientiﬁc literature, speciﬁcally
in  electronic databases: Medline/Pubmed, SciELO, EMBASE and Cochrane, and the following
descriptors were used: ulcerative colitis, acute colitis, clinical treatment, surgery and ran-
domized trial. It can be concluded that the goals of therapy in ulcerative colitis are clinical
and  endoscopic remission, deep, sustained remission without corticosteroids, prevention
of  hospitalizations and surgeries, and improved quality of life. The surgical indications
are  reserved for selected cases, ranging from medical intractability, complications (severe
refractory acute colitis, toxic megacolon, perforation and hemorrhage) and malignancy.
Information in this review article must be submitted to evaluation and criticism of the spe-
cialist responsible for the conduct to be followed, in the face of his/her reality and the clinical
status of each patient.
The degree of recommendation and strength of evidence were based using the GRADE sys-
tem  (The Grades of Recommendation, Assessment, Development, and Evaluation) described
below:
1.  A: Experimental or observational studies of higher consistency.
2. B: Experimental or observational studies of lower consistency.
3.  C: Case reports (non-controlled studies).
4. D: Opinion without critical evaluation, based on consensus, physiological studies or
animal models.
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Tratamento  da  retocolite  ulcerativa:  atualizac¸ão  clínica
Palavras-chave:
Colite ulcerativa
Colite aguda
Tratamento clínico
Cirurgia
Complicac¸ões
r  e  s  u  m  o
O objetivo deste trabalho foi avaliar os consensos de sociedades de especialistas e guide-
lines  publicados sobre o manejo da retocolite ulcerativa, e confrontar com a experiência
dos  autores, a ﬁm de padronizar condutas que auxiliem o raciocínio e a tomada de decisão
do  médico. Foi realizada busca na literatura cientíﬁca, mais precisamente nas bases de
dados eletrônicos: Medline/Pubmed, SciELO, EMBASE e Cochrane, tendo sido utilizado os
descritores: ulcerative colitis, acute colitis, clinical treatment, surgery e randomized trial.
Pode-se concluir que os objetivos da terapia na retocolite ulcerativa são: remissão clínica e
endoscópica, a remissão profunda sustentada sem corticosteróides, evitar hospitalizac¸ões
e  cirurgias, e melhora na qualidade de vida. As indicac¸ões cirúrgicas ﬁcam reservadas para
casos selecionados que variam de intratabilidade clínica, complicac¸ões (Colite aguda grave
refratária, megacólon tóxico, perfurac¸ão e hemorragia) e malignizac¸ão. As informac¸ões
contidas neste artigo de revisão devem ser submetidas à avaliac¸ão e à crítica do médico
especialista, responsável pela conduta a ser seguida, frente à sua realidade e ao estado
clínico de cada paciente.
O grau de recomendac¸ã˜o e forc¸¸a de evidência foram baseados usando o GRADE system
(The  Grades of Recomendation, Assessment, Development, and Evaluation), descrito abaixo:
A:  Estudos experimentais ou observacionais de melhor consistência.
B:  Estudos experimentais ou observacionais de menor consistência.
C:  Relatos de casos (estudos não controlados).
D:  Opinião desprovida de avaliac¸ão crítica, baseada em consensos, estudos ﬁsiológicos
ou  modelos animais.
©  2015 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
Todos os direitos reservados.
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ontroduction  and  epidemiology
onspeciﬁc ulcerative rectocolitis (NURC) is a chronic inﬂam-
atory bowel disease (IBD) with a not fully understood
tiology that manifests itself preferably in young people and
hose main symptoms are a mucous and bloody diarrhea,
ith or without abdominal pain (A).
Its symptoms depend on the extent and severity of the
isease; when limited to the rectum (proctitis), NURC tends
o exhibit intense mucorrhea, tenesmus, fecal incontinence
nd defecation urgency. In severe cases of colitis, other asso-
iated symptoms such as vomiting, fever, anorexia, bloating
nd abdominal distension can emerge.
The disease tends to begin in the rectum and then extends
ranially, affecting uniformly and also continuously the prox-
mal segments, presenting a distal gradient.
In recent decades, an exponential increase in IBD has been
escribed worldwide. There is evidence that these diseases
ave a direct relationship with industrial progress, which
ould justify its increasing incidence in some countries in
ecent decades, even in those hitherto classiﬁed as of low
requency (B).
There is wide variation between the incidence rates of IBD.
n Europe, incidence rates range from 4.1/100,000 (Romania)
o 81.5/100,000 (Faroes Islands).1 With regard to ulcerative col-
tis, one recent systematic review estimated that the incidence
n Europe ranged from 0.4 to 24.3 new cases diagnosed per
00,000 inhabitants (A).2 In Asia and the Middle East, on the
ther hand, the incidence was lower: 0.1–6.3/100,000.2 On theother hand, in North America the incidence of NURC had inter-
mediate rates, ranging from 0 to 19.2/100,000 population.3
As the prevalence of NURC, the most recent data available
in the literature are from a population-based study published
at the beginning of 2014 that showed a slight increase in
Scandinavia (C).4 Currently there are about 61,000 patients
diagnosed with IBD in Sweden, and most patients are carri-
ers of NURC, with a prevalence of 0.35% (95% CI: 0.34–0.35).5
It has also been observed that the prevalence of IBD is higher
in countries of the northern hemisphere, that is, those closer
to the Arctic.6 In Finland the prevalence of NURC was higher
in Oulu and Tampere, cities located further north, compared
to Helsinki, a city located further south in that Scandinavian
country (C).7
In Brazil, an epidemiological study conducted by the Botu-
catu Medical School evaluated the incidence and prevalence
of IBD in a micro-region of São Paulo state. During the period
from 1986 to 2005, an increase in incidence was observed over
this time, but with lower values when incidence rates were
compared worldwide, that is, the incidence rate in this region
is low, matching Latin America and southern Europe countries
(C).8 It is noteworthy that its incidence has an inverse relation
with smoking.
Signs  and  symptoms
NURC usually affects young patients in the second to the
fourth decade of life, regardless of gender. The inﬂammatory
process is restricted to colorectal mucosa and submucosa and
can manifest itself from a mild form to a severe colitis with
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Disease severityScores (Points)
Clinical remission≤ 2 and no subscore >1
Mild activity3-5
Moderate activity6-10
Severe activity 11-12 
aThe global medical evaluation takes into account the daily complaint of the patient with regard
to abdominal discomfort, pain, a feeling of well-being (normal, above or below the average),
physical examination findings and the patient’s performance of daily activities.
Frequency of bowel movements Rectal Bleeding
0 = No blood0 = Normal for the patient  
1 = 1-2 stools/day in addition to the usual
2 = 3-4 stools/day in addition to the usual
3 = Bowel movements with fresh blood
2 = Evidence of fresh blood in most of the evacuations  
1 = Blood streaks in less than half of evacuations
3 = >5 stools/day beyond the usual 
Endoscopic findings
0 = Normal mucosa or inactive disease
1 = Mild disease (enanthema, loss of vascular pattern, mild friability)
2 = Moderate disease (obvious enanthema, loss of vascular pattern, friability, erosions)
3 = Severe disease (spontaneous bleeding, ulceration)
Global Medical Assessmenta
0 = Normal
1 = Mild disease
2 = Moderate disease
3 = Severe disease
veriFig. 1 – Mayo Clinic Score: se
systemic involvement. The disease can be limited to the rec-
tum (proctitis); can involve the left semicolon (left colitis) or
often extends throughout the colon (pancolitis).
Thus, the signs and symptoms vary according to the extent
and intensity of the inﬂammatory process, although there is
not always proportionality between the extent of disease and
severity of symptoms (A).
The clinical picture consists of episodes of diarrhea of mod-
erate to severe intensity, most often accompanied by fresh
blood and/or mucus, usually preceded by abdominal cramps,
and with relief after defecation. This increase in bowel rhythm
can occur during the day or at night. Other symptoms may be
present, such as anorexia, fever, asthenia, defecation urgency,
ﬂatulence, and tenesmus; the severity of diarrhea tends to cor-
relate with the extent and severity of colonic inﬂammation (A).
The abdominal pain varies according to the intensity of
inﬂammation, being generally of mild to moderate type, but
may become severe in complications such as fulminant colitis
and toxic megacolon.
Extra-intestinal conditions may be present, such as joint,
dermatological, ophthalmologic, hepatobiliary and hemato-
logic manifestations that may precede or appear after the
intestinal event.
Classiﬁcation  of  severity
The disease can be classiﬁed according to the clinical picture,
in association with laboratory and endoscopic parameters.
In the 1960s, a study published by University of Oxford
(UK) investigators, produced the Truelove-Witts classiﬁcation
(1955).9 However, the English classiﬁcation did not include
critical parameters to assess the severity of the disease, asty index of ulcerative colitis.
well as endoscopic ﬁndings and the general condition of the
patient. In 1987, the Mayo Clinic group in Rochester, Minnesota
(USA),10 published a classiﬁcation that has become the most
widely used in the literature, both in clinical practice and in
most of the trials involving patients with NURC (Fig. 1). The
disease can be classiﬁed as mild, moderate or severe, and 2/3
of patients exhibit a mild-to-moderate picture (A).10 The treat-
ment is based on the intensity and extent of the inﬂammatory
process.
Diagnosis
There is no single test that can be considered the “gold
standard” for the diagnosis of NURC. The diagnosis of this con-
dition is based on data from the clinical history and physical
examination, together with laboratory tests and radiologi-
cal, endoscopic and histological studies. The main tests are
colonoscopy, pathology, serum and fecal biochemical tests and
radiological studies (D).11
Colonoscopy
Unlike Crohn’s disease, NURC is characterized by a diffuse
mucosal and submucosal inﬂammation limited to the colon
and rectum. A few patients may experience an inﬂammation
of 5–10 cm from terminal ileum that was referred to as reﬂux
ileitis or “backwash ileitis”; there is controversy as to whether
this ﬁnding is related or not with disease severity.Colonoscopy with biopsy of the mucosa is the test of choice,
since it can establish the diagnosis and assess the extent
and severity of the disease, and also allows the collection
of material for histological analysis and cultures. In patients
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Table 1 – Classiﬁcation of Montreal (2006) – according to
URC location.
Ulcerative
rectocolitis – URC
Classiﬁcation of Montreal
E 1 – Proctitis Limited to rectum (30%)
E 2 – Left Sided Colitis Affects the rectum and left colon
(distal to the splenic ﬂexure) (40%)
E 3 – Pancolitis Affects the rectum and colonj coloproctol (rio j). 
ith active NURC, one can observe a continuous and diffuse
nﬂammatory process with edema, congestion, friability and
ranularity of the mucosa, and microulcerations that may or
ay not be covered by ﬁbrin. In 95% of the time, the rectum
s compromised by the inﬂammatory process; on the other
and, rarely the terminal ileum will be affected (5%). Another
requent endoscopic ﬁnding is the inﬂammation gradient, in
hich a more  intense involvement in the rectum and a milder
nvolvement in proximal segments are observed.
In addition, the histological evaluation is critical to the
iagnosis of this disease, in staging procedures the degree of
nﬂammation, in the follow-up after the beginning of treat-
ent, and even to exclude dysplasia and cancer associated to
URC (B).11,12
It is of the utmost importance a good integration between
he surgeon, endoscopist and pathologist to improve diagnos-
ic accuracy (A).11
omplementary  tests
ome tests may help in assessing the severity of inﬂamma-
ion. Serum levels of C-reactive protein (CRP) and erythrocyte
edimentation rate (ESR) are useful tests in the evaluation of
he inﬂammatory process, but these are not speciﬁc and must
e analyzed in conjunction with other clinical, endoscopic,
adiological and histopathological data (B).11–13
Some serological markers as pANCA and ASCA, although
ot speciﬁc, can predict years ahead (in case of a positive
esult) if the patient will develop inﬂammatory bowel disease;
hese markers are also valuable in differentiating colitis and
rohn’s disease. There is also evidence that pANCA-positive
URC patients are at a higher risk of being colectomized,
hich may reﬂect greater disease severity (B).11–13
Fecal calprotectin is a newly added test to the clinical arma-
entarium; this is a very sensitive test for the diagnosis of
owel inﬂammation, although with little speciﬁcity. Fecal cal-
rotectin reﬂects the presence of inﬂammation, and there is
 direct correlation of their lives with the severity and of the
xtent the inﬂammatory process.
Thus, this test is very useful in monitoring the response
o treatment, as well as in the diagnosis of relapses. Nega-
ive levels should not be interpreted as a lack of bowel organic
athology, but as the absence of an inﬂammation caused by
eutrophils (B).13,14
In patients treated with biological agents and beneﬁted
ith good clinical and endoscopic response, a sharp drop in
ecal calprotectin level is observed, which shows good correla-
ion with the mucosal healing process.11,14 It can be concluded
hat the clinical disease activity index, in association with
erum and fecal markers, increases the accuracy in determin-
ng and predicting the acutization stage of the disease and to
onitor the response to treatment.11,12
reatment
he treatment of ulcerative colitis is based on severity, activity,
ocation and extent of the disease. Considering that in gen-
ral NURC involves more  distal segments of the large bowel
rectum and sigmoid), this disease can be classiﬁed, according
o its location, into 3 groups (Montreal Classiﬁcation, Table 1).proximal to the splenic angle (30%)
As to the severity of the disease, it can be considered mild,
moderate or severe, based on the aforementioned criteria. It
is noteworthy that the vast majority of patients experience
mild-to-moderate illness (85%) and the rest presents with the
severe form (15%).15–17
The main goals of NURC management are clinical remis-
sion of active disease, remission maintenance without
corticosteroids, prevention of complications, and improve-
ment of the quality of life. However, since the advent of
the management with biological agents (and in line with
the management of Crohn’s disease), the healing process of
the inﬂamed intestinal mucosa must be an objective to be
pursued, since there is evidence that an effective control of
inﬂammation is associated with a decrease in rates of recur-
rence of the disease, reducing the need for hospitalization and
even in the number of colectomy indications (B).17
Table 2 lists the main drugs, routes of administration, and
dosages.
The treatment of NURC is based on the extent and activity
of the disease.17,18
Proctitis
The ﬁrst-line therapy for active colitis limited to the rec-
tum (proctitis) is topical mesalazine (A).9 A systematic review
from of 38 clinical trials from Cochrane database on procti-
tis and left colitis management conﬁrmed the superiority of
this therapy versus placebo for the induction of clinical remis-
sion, besides endoscopic and histological improvement. In a
head-to-head comparison, topical mesalazine, is also better
than oral mesalazine, being more  effective than topical cor-
ticosteroids to achieve clinical, endoscopic and histological
remission (A).19,20
Mesalazine 1 g/day in suppository is the initial treatment
for mild or moderate proctitis; one alternative is the use of
mesalazine enema (A).19,20 In this sense, the suppository is
better tolerated, its application is easier and shows the bet-
ter rectal distribution of the drug, with no difference in the
application in a single versus divided dose.
The combined use of oral and topical mesalazine, or
with a topical steroid, may be tried in those cases with
no initial improvement; this is the second treatment option
(A).18–20 In the staggered therapeutic sequence, if the afore-
mentioned therapies were unsuccessful, the physician can
suggest the use of immunosuppressants and/or biological
therapy.17,18
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Table 2 – Main drugs used to treat ulcerative colitis.
Drug Commercial brand Presentation Initial dose Maintenance dose
Mesalazine Pentasa Tablets  500 mg 3  g–4 g 1 g–2 g
Sachets de 1 g and 2 g
Mesalazine Pentasa Suppository 1 g 500 mg
Mesalazine Pentasa Enema 1 g 1 g 1 g
Mesalazine Mesacol Tablets 400 and 800 mg 2.4–4 g 1.6–2.4 g
Mesalazine Mesacol Suppository 500 mg 1 g 500 mg
Mesalazine Mesacol MMX Tablets 1.2 g 3.6–4.8 g 1.2–2.4 g
Sulfasalazine Azulﬁn Tablets 500 mg 4–5 g 2 g
Sulfasalazine Azulﬁn Suppository 1 g 500  mg
Azathioprine Imuran Tablets 50 mg 2–2.5  mg/kg 2–2.5 mg/kg
Inﬂiximab Remicade Ampoules 100 mg 5 mg/kg weight at weeks
0, 2 and 6
5  mg/kg every 8 weeks
mg Adalimumab Humira Preﬁlled syringe 40 
Left  Sided  Colitis
The treatment of choice in cases of mild-to-moderate left
sided colitis is a combination of oral and topical mesalazine;
there is evidence that the concentration levels of 5-ASA in
the rectal mucosa are greater in the combined therapy versus
monotherapy with this agent (A).19,20
This combined effect is more  signiﬁcant when the dis-
ease extends by at least 50 cm above the anal margin, that is,
a proctosigmoiditis.12,13 A recent meta-analysis showed that
mesalazine is superior to placebo in inducing and maintain-
ing clinical remission in patients with NURC (number needed
to treat [NNT] = 6). Doses of mesalazine over 2 g/day were
more effective than doses < 2 g/day in the prevention of clinical
recurrence.19
Furthermore, the ASCEND II study demonstrated that
mesalazine 4.8 g/day produced better scarring process/clinical
response rate versus 2.4 g/day.21 As to enemas, the recom-
mended dose is 1 g/day, with no difference between large-
or low-volume enemas, the latter being better tolerated by
patients (A).13,22 Although there is controversy among some
meta-analyze, the use of rectal corticosteroids (enema) seems
to be equivalent to the topical use of 5-ASA.22,23 Adherence
to treatment with salicylates is a serious problem that can
impact about 40–60% of patients. There is evidence that low
adherence to treatment regime is related to a dosing regime
higher or equal to 3 daily doses (A).13,20
With the new formulations of mesalazine (mesalazine in
sachet, or MMX®), patients can take a higher dose, and the
result is a smaller number of daily doses, thus improving
adherence to treatment.
The MOTUS study compared the use of mesalazine (sachet)
4 g taken in two doses of 2 g every 12 h versus a single dose
of 4 g per day. Clinical remission at 8 weeks for patients
treated with a single dose of mesalazine was 52.1% com-
pared to 41.8% in those treated with two daily doses (p = 0.14).
The rates of mucosal healing and the improvement in symp-
tom scores (UC-DAI) were statistically better versus in those
patients treated with 2 doses/day24 (B).In cases not beneﬁted with a good clinical response with
the use of salicylic derivatives after 14–21 days of treatment, or
in cases of disease exacerbation, corticosteroids can be added.160 mg SC at weeks 0
and 80 mg at week 2
40 mg SC every 2 weeks
Prednisone is the corticosteroid most often used, with a sug-
gested dose of 0.75–1 mg/kg/day, with a maximum dose of
60 mg/day. Prednisone is a synthetic glucocorticoid of inter-
mediate power, being converted in the liver into prednisolone,
the active form. The average daily dose is 40 mg/day for 1–2
weeks or until the occurrence of clinical remission; at this
point, the corticosteroid must be reduced (10 mg/week, until
5 mg/kg/day), when the drug will be gradually reduced (5 mg
each week) until its complete discontinuation.23
If, during the corticosteroid weaning process, the disease
relapses, the dose should be increased to the penultimate
dose preceding that in which the relapse occurred; after-
wards, the gradual discontinuation of procedure will be
carried on. The salicylic derivatives should be maintained for
long periods, in order to minimize the chance of relapse. In
case of steroid dependence (inability to reduce the dose of
20 mg/day without the occurrence of relapse) or in cases of
refractoriness to corticosteroids (no response to treatment
with prednisone 60 mg/day after 4–6 weeks of therapy) the
physician should suggest the use of immunomodulators (aza-
thioprine, 6-mercaptopurine) (A).24
Azathioprine at a dose of 2–2.5 mg/kg/day is the main
immunomodulator or immunosuppressant used in clinical
practice. Azathioprine is a synthetic analog of purine and was
developed in the ﬁnal years of the 1950s. This is a pro-drug
of 6-mercaptopurine and acts by inhibiting DNA synthesis in
proliferating cells, for instance, B and T lymphocytes.25,26
The side effects of immunomodulation agents (azathio-
prine and 6-mercaptopurine) occur in around 12–15% of cases,
and may be of allergic (fever, skin rash, nausea, vomiting,
abdominal pain, diarrhea, hepatitis, or pancreatitis) or non-
allergic (bone marrow depression, infections and neoplasia)
origin. The most severe side effect is bone marrow aplasia,
especially in those patients with deﬁciency of the enzyme
thiopurine S-methyltransferase (TPMT). The full effect of the
drug occurs 12–16 days after the beginning of treatment,
considering its delayed action. The drug should not be used in
inducing clinical remission, but in a therapy of maintenance.
A meta-analysis of the Cochrane Foundation revealed that
the use of azathioprine is effective in maintaining remission in
patients with NURC whose treatment with salicylates failed,
or requiring several treatments with steroids to obtain the
induction of remission. The long-term use of corticosteroids
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ust be avoided, as well as its frequent reintroductions. How-
ver, the study concluded that there is little evidence that
he use of azathioprine, as a maintenance drug, is superior
o salicylates (A).25
Other immunomodulatory drugs such as 6-mercaptopur-
ne (1–1.5 mg/kg/day) and methotrexate (15–25 mg/week) can
lso be used in refractory cases. A meta-analysis published
ecently showed that about 2/3 of patients refractory to aza-
hioprine may beneﬁt from the use of 6-mercaptopurine in
aintaining remission in patients with NURC (B).26
ancolitis  or  extensive  colitis
ild-to-moderate cases of pancolitis should be treated simi-
arly to the treatment given to patients with left colitis, that is,
ith oral mesalazine 4–4.8 g/day associated with mesalazine
nema 1 g/day (A).13,17,22
Likewise, if the symptoms persist after 14–21 days of treat-
ent or if a sustained relief of symptoms has not been
chieved after 30–40 days of treatment with mesalazine,
ne can introduce an induction therapy with oral corti-
osteroids (prednisone) at an average dose of 40 mg/day
0.75–1 mg/kg/day – not exceeding 60 mg/day). The mainte-
ance treatment is carried out with mesalazine 2–2.4 g/day
A).23,24
Patients with proctitis, left colitis or mild-to-moderate pan-
olitis refractory to conventional therapy with salicylates and
mmunomodulators should be treated with biological agents
ombined with azathioprine, or as monotherapy (B).13,25,27,28
roctitis,  left  colitis  or  moderate-to-severe
ancolitis  refractory  to  conventional  treatment
nﬂiximab is a chimeric monoclonal antibody anti-TNF (tumor
ecrosis factor), being indicated for patients with NURC
efractory to conventional therapy. (B) Two randomized,
lacebo-controlled studies published in 2005, ACT 1 and ACT
, showed that the use of inﬂiximab at a dose of 5 mg/kg
as superior to placebo in the treatment of patients with
oderate-to-severe ulcerative colitis refractory to conven-
ional therapy with salicylates and azathioprine.28,29
Patients treated with inﬂiximab had a better clinical
esponse and improved clinical remission and mucosal heal-
ng versus patients treated with placebo. Inﬂiximab should be
sed intravenously at a dose of 5 mg/kg body weight, with
n induction dose at week 0, another dose 2 weeks after the
rst, and a third dose 6 weeks after the initial dose (Induction
herapy: weeks 0, 2 and 6). Maintenance therapy must be per-
ormed with infusions every 8 weeks at a dose of 5 mg/kg.28,29
Currently, there is evidence that the use of inﬂiximab
n combination with azathioprine is superior to monother-
py with inﬂiximab or with azathioprine in patients with
oderate-to-severe NURC refractory to salicylates, corticoste-
oids, and immunomodulators.30The SUCESS study revealed that patients treated with
nﬂiximab combined with azathioprine had a better clinical
esponse, clinical remission and a mucosal healing process,
hen compared with those who received monotherapy (B).30;3 5(4):230–237 235
Recently, at the end of 2014, ANVISA approved the use of
adalimumab, another anti-TNF agent, indicated for the treat-
ment of moderate-to-severe NURC refractory to conventional
therapy. Adalimumab is a fully human monoclonal anti-
body which binds effectively to soluble and transmembrane
TNF. The pivotal studies ULTRA (Ulcerative Colitis Long-Term
Remission and Maintenance with Adalimumab) 1 and 2 eval-
uated patients with NURC refractory to conventional therapy
treated with adalimumab and compared them with those
treated with placebo. As observed in studies with inﬂiximab,
NURC patients refractory to conventional therapy and treated
with adalimumab had a better clinical response and improved
clinical remission, besides a better mucosal healing versus
those treated with placebo. Adalimumab should be used sub-
cutaneously at a loading dose of 160 mg  given at week 0, with
80 mg  administered at week 2. The maintenance dose is 40 mg
SC administered every 2 weeks.23,31,32
We  conclude that there is strong scientiﬁc evidence
regarding the effectiveness of anti-TNF agents (inﬂiximab
and adalimumab) in the management of moderate-to-severe
NURC refractory to conventional treatment. Recent meta-
analysis with over 2200 patients enrolled in randomized
trials showed that, in patients treated with inﬂiximab or
adalimumab, a lower number of hospitalizations and fewer
complications occurred. Those who were treated with inﬂix-
imab also were less likely to be colectomized. Furthermore,
the use of anti-TNF agents in patients with NURC was not
associated with an increased risk of serious adverse effects
(A).33
Severe  acute  colitis  of  any  extent
Severe acute ulcerative colitis is a potentially fatal condition
that has been described by Truelove & Witts in 1954, who
used the following criteria for its deﬁnition: bloody diarrhea (>
episodes/day), anal bleeding, fever (>37.8 ◦C), tachycardia (HR
>90 bpm), anemia (Hb <10.5 g/dL) and increased erythrocyte
sedimentation rate (ESR >30 mm).9 Other clinical parameters
must be evaluated at admission: degree of hydration, ane-
mia, and malnutrition. All patients meeting criteria for severe
colitis should be hospitalized for treatment in the intensive
care unit with a multidisciplinary approach (coloproctologist,
gastroenterologist, a nutrition specialist, psychologist, and
nurse). Despite the fact that cases of severe acute colitis often
are associated with inﬂammatory bowel disease, this disease
can have other causes that should be investigated at admis-
sion and, if present, treated: infectious colitis by Clostridium
difﬁcile, cytomegalovirus, shigella, salmonella, and enterohe-
morrhagic E. coli, among others.
Prevention of thromboembolic disease is mandatory.
Where required, patients should receive enteral or parenteral
nutritional support, intravenous corticosteroids and broad-
spectrum antibiotics.
In acute or fulminant colitis, the drug of choice is hydro-
cortisone 300–400 mg/day or methylprednisolone 60 mg/day,
which may be administered by continuous infusion or divided
into 3–4 applications. (B) The patient should be reevaluated
2–3 times a day, and complications such as toxic mega-
colon, profuse bleeding, and intestinal perforation should
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be averted. Toxic megacolon is characterized by an acute
dilation of the colon (colon >5.5 cm diameter), in asso-
ciation with signs of toxemia (fever, tachycardia, pain,
bloating, confusion, anemia and leukocytosis). In the face
of a diagnostic suspicion, one should avoid using narcotics,
nonsteroidal anti-inﬂammatory drugs, and antidiarrheals,
which can worsen the clinical picture. Furthermore, bar-
ium enema and colonoscopy should also be avoided. The
treatment consists of supportive measures, fasting, hydra-
tion, intravenous corticosteroids, antibiotics (ciproﬂoxacin
1–1.5 g/day) and metronidazole 20–30 mg/kg/day and cef-
triaxone 2 g/day + metronidazole 20–30 mg/kg/day); and, if
needed, a blood transfusion. On the other hand, an acute per-
forated abdomen is an indication of emergency surgery.
The patient severely affected should be evaluated carefully;
and in the absence of clinical and laboratory improvement
after 3–4 days of parenteral corticosteroid therapy, a res-
cue therapy (cyclosporine or inﬂiximab) should be instituted
(B).34,35 The use of inﬂiximab in this scenario, at a dose of
5 mg/kg of body weight, has been shown to be effective in
preventing colectomy both in short- and long-term (B).36,37
Thus, it is critical that all patients with severe IBD (Crohn
disease or NURC) or frequent relapses undertake screening
tests (PPD-Mantoux reaction and chest Rx), serology for hep-
atitis, and – in emergency situations – collection of samples
for tests in the face of any need for biologic or immunosup-
pressive therapy. For this purpose, it is important to be with
vaccination updated.
If, after 48–72 h, no improvement with salvage therapy was
observed and if the patient’s condition worsens, or also if a
bowel perforation was diagnosed, the surgical option will be
mandatory. In emergency situations with peritoneal contami-
nation and in patients who  require surgery and who are being
treated with prednisone/prednisolone (dose >20 mg/day for
over 6 weeks), the surgery must be performed in 2 or 3 sur-
gical times. (B) In a ﬁrst surgical time, total colectomy with
ileostomy and burial of the rectum at the level of (or slightly
above) the peritoneal reﬂection; and in a second time, with the
reconstruction of bowel transit.38,39
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